Articles
Circadian closes $17.4m capital raising
Circadian Technologies (ASX:CIR) has raised $17.4m through a placement and share purchase plan, and plans to use the proceeds to take OPT-302 into the clinic in wet AMD. [ + ]
GID resumes EndoBarrier shipments in EU
GI Dynamics (ASX:GID) has received the all-clear to resume shipments of its EnBobarrier obesity and diabetes therapy in the EU following a two-month suspension. [ + ]
Genetic Technologies searching for new CEO
Genetic Technologies (ASX:GTG) has announced the resignation of CEO Alison Mew, and has secured shareholder approval to change its name to Phenogen Sciences. [ + ]
New report on medtech industry's global performance
EY has released its annual medical technology report for 2014 - 'Pulse of the industry: differentiating differently'. [ + ]
Novogen identifies lead anti-tropomyosin drug
Novogen (ASX:NRT) has selected the lead candidate from its family of drugs designed to complement existing chemotherapies by targeting a different part of a cancer's cytoskeleton. [ + ]
The bioprinted liver
Bioprinted liver tissue containing both parenchymal and non-parenchymal cells in spatially controlled, user-defined geometries that reproduce compositional and architectural features of native tissue are making it possible to assess drug effects over timeframes much longer than those offered by 2D liver cell culture systems.
[ + ]CSL commences phase IIb heart attack trial
CSL (ASX:CSL) has launched a trial of CSL112 in patients at risk of recurrent cardiovascular events and presented data into the cholesterol-clearing mechanism of action behind the drug. [ + ]
GTG completes Australian genetics sale
Genetic Technologies (ASX:GTG) has completed the sale of its Australian genetics business to Specialist Diagnostics Services as part of its streamlining efforts. [ + ]
The gene genie: controlling genes with your thoughts
Researchers at ETH Zurich have created the first gene network to be operated via brainwaves. Depending on the user's thoughts, it can produce various amounts of a desired molecule.
[ + ]Close encounters of a comet kind - Rosetta and Philae's scientific payloads
In March 2004, the spacecraft Rosetta was launched by the European Space Agency - its mission to orbit and land on the comet 67P/Churyumov-Gerasimenko. To complete the most detailed study of a comet ever attempted, the orbiter carried 11 science experiments and its lander, Philae, carried 10 additional instruments. [ + ]
Alchemia CEO leaves as Calzada gets a new one
Alchemia (ASX:ACL) has announced the sudden departure of CEO Thomas Liquard, Calzada (ASX:CZD) has appointed a new CEO and Patrys (ASX:PAB) has added to its board. [ + ]
CSL completes $500m placement
CSL (ASX:CSL) has completed a debt placement worth nearly $500m to help pay for capital management activities including its $900m share buyback. [ + ]
A meeting of the minds
An international research collaboration has built a pathway that makes brain-to-brain communication possible - with a little help from the internet. [ + ]
Novogen CEO to hand over chairman role
With Novogen (ASX:NRT) moving to take anticancer candidate Cantrixil into the clinic, the company is making moves to line up funding and allow it to better focus on clinical development. [ + ]
'Frankenstein' DNA keeps tumours alive
Australian researchers have discovered how the massive DNA molecules that appear in some tumours are stitched together from other parts of the genome, making them similar to Frankenstein's monster. [ + ]